Trial Profile
An Open, Dose Escalation, Single Dose Study to Assess Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2019
Price :
$35
*
At a glance
- Drugs Hitanercept (Primary)
- Indications Rheumatic disorders
- Focus Adverse reactions; First in man
- Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- 12 Jun 2017 Results published in the European Journal of Clinical Pharmacology
- 08 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Nov 2014 New trial record